MLTX (MoonLake Immunotherapeutics) Ending Cash Position: $298.49 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLTX MoonLake Immunotherapeutics MLTX
28 GF Score
Price $19.69
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics Ending Cash Position?

MoonLake Immunotherapeutics MLTX +3.52% 28 Ending Cash Position is $298.49 Mil as of Mar. 2026. GuruFocus rates MLTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

MoonLake Immunotherapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $298.49 Mil.

MoonLake Immunotherapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($350.74 Mil) to Dec. 2025 ($334.52 Mil) and declined from Dec. 2025 ($334.52 Mil) to Mar. 2026 ($298.49 Mil).

MoonLake Immunotherapeutics's annual Ending Cash Position declined from Dec. 2023 ($451.17 Mil) to Dec. 2024 ($180.43 Mil) but then increased from Dec. 2024 ($180.43 Mil) to Dec. 2025 ($334.52 Mil).

MoonLake Immunotherapeutics Ending Cash Position Related Terms

MoonLake Immunotherapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics Ending Cash Position Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.00 39.51 451.17 180.43 334.52

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 271.57 306.68 350.74 334.52 298.49
MLTX
28GF Score
MoonLake Immunotherapeutics MLTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MoonLake Immunotherapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=180.426+154.091
=334.52

MoonLake Immunotherapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=334.517+-36.027
=298.49

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $298.49 Mil mean?
MoonLake Immunotherapeutics (MLTX) has a Ending Cash Position of $298.49 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MoonLake Immunotherapeutics and its competitors.
Is MoonLake Immunotherapeutics' Ending Cash Position too high?
MoonLake Immunotherapeutics' current Ending Cash Position is $298.49 Mil. Overall, MoonLake Immunotherapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Ending Cash Position compare to FTRE and SEPN?
MoonLake Immunotherapeutics' Ending Cash Position of $298.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current Ending Cash Position is $298.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MLTX) has a current Ending Cash Position of $298.49 Mil. The current Ending Cash Position is $298.49 Mil. MoonLake Immunotherapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MLTX), the current Ending Cash Position is $298.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
28GF Score

Get the complete analysis for MLTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.69
Price